Shopping Cart 0
Cart Subtotal
AED 0

EUROPE INFERTILITY TESTING MARKET Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 15414

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 19818

Details

The Europe Infertility Testing Market is accounted to reach USD 5,786.90 million by 2024, from USD 3,390.16 million in 2016 growing at a CAGR of 7.0% in the forecast period 2017 to 2024.

The major factors driving the growth of market are raising public awareness among the female population and increasing number of gynecological disorders

The key market players for Europe Infertility Testing Market are listed below:

The Europe Infertility Testing Market is accounted to reach USD 5,786.90 million by 2024, from USD 3,390.16 million in 2016 growing at a CAGR of 7.0% in the forecast period 2017 to 2024.

The major factors driving the growth of market are raising public awareness among the female population and increasing number of gynecological disorders

The key market players for Europe Infertility Testing Market are listed below:

Merck KGaA

Proctor & Gamble.

bioMerieux SA

VIDAS Fertility panel,

BIONEXIA hCG Combo

The market is further segmented into:

Type

Material

End User

Geography

The Europe infertility testing market is segmented on the basis of type, test kits, prescription mode, distribution channel and end user.

Based on type, the global infertility testing market is segmented into female infertility testing and male infertility testing. The infertility testing market is dominated by female infertility testing with 57.6% market share in 2017, growing at the highest CAGR of 7.5% in the forecast period. Based on type, female infertility testing is further segmented into ovulation testing, hysterosalpingography, laparoscopy, transvaginal ultrasound, ovarian reserve testing, hormone tests and others. Male infertility testing is sub segmented into DNA fragmentation, oxidative stress analysis, sperm penetration assay, computer aided semen analysis, sperm agglutination, microscopic examination and others.

Based on of test kits are further sub divided into human Follicular Stimulating Hormone (FSH) urine test kits, luteinizing hormone (LH) urine test kits, human chorionic gonadotropin (HCG) hormone blood test kits and others. In 2017, the Luteinizing Hormone (LH) Urine Test kits are expected to dominate the market with 40.3% market share

Based on prescription mode, the global infertility testing market is segmented into prescription-based and over the counter (OTC) based. In 2017, over the counter (OTC) segment is expected to dominate the market with 82.56% market share.

Based on distribution channel, the global infertility testing market is classified into hospitals pharmacies, online pharmacies and pharmacies & drug stores. In 2017, the pharmacies & drug stores are expected to dominate the market with 49.6% market share.

Based on end user, the global infertility testing market is classified into fertility centers, hospitals and clinics, research institutes and cryobanks. In 2017, the Fertility Centres are expected to dominate the market with 39.7% market share.

Based on geography, the Europe Infertility Testing market is segmented into geographical regions, such as,

Germany,

United Kingdom,

France,

Spain,

Italy,

Russia,

Turkey,

Belgium,

Nether lands,

Switzerland,

Rest of Europe

Covered in this report

The report covers the present scenario and the growth prospects of the Europe Infertility Testing market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Merck KGaA

Proctor & Gamble.

bioMerieux SA

VIDAS Fertility panel,

BIONEXIA hCG Combo

The market is further segmented into:

Type

Material

End User

Geography

The Europe infertility testing market is segmented on the basis of type, test kits, prescription mode, distribution channel and end user.

Based on type, the global infertility testing market is segmented into female infertility testing and male infertility testing. The infertility testing market is dominated by female infertility testing with 57.6% market share in 2017, growing at the highest CAGR of 7.5% in the forecast period. Based on type, female infertility testing is further segmented into ovulation testing, hysterosalpingography, laparoscopy, transvaginal ultrasound, ovarian reserve testing, hormone tests and others. Male infertility testing is sub segmented into DNA fragmentation, oxidative stress analysis, sperm penetration assay, computer aided semen analysis, sperm agglutination, microscopic examination and others.

Based on of test kits are further sub divided into human Follicular Stimulating Hormone (FSH) urine test kits, luteinizing hormone (LH) urine test kits, human chorionic gonadotropin (HCG) hormone blood test kits and others. In 2017, the Luteinizing Hormone (LH) Urine Test kits are expected to dominate the market with 40.3% market share

Based on prescription mode, the global infertility testing market is segmented into prescription-based and over the counter (OTC) based. In 2017, over the counter (OTC) segment is expected to dominate the market with 82.56% market share.

Based on distribution channel, the global infertility testing market is classified into hospitals pharmacies, online pharmacies and pharmacies & drug stores. In 2017, the pharmacies & drug stores are expected to dominate the market with 49.6% market share.

Based on end user, the global infertility testing market is classified into fertility centers, hospitals and clinics, research institutes and cryobanks. In 2017, the Fertility Centres are expected to dominate the market with 39.7% market share.

Based on geography, the Europe Infertility Testing market is segmented into geographical regions, such as,

Germany,

United Kingdom,

France,

Spain,

Italy,

Russia,

Turkey,

Belgium,

Nether lands,

Switzerland,

Rest of Europe

Covered in this report

The report covers the present scenario and the growth prospects of the Europe Infertility Testing market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Table Of Content

Scope

Table Of Contents

1. Introduction 29

1.1. Objectives Of The Study 29

1.2. Market Definition 29

1.3. Overview Of Europe Infertility Testing Market 29

1.4. Currency And Pricing 30

1.5. Limitation 30

1.6. Markets Covered 31

2. Market Segmentation 33

2.1. Markets Covered 33

2.2. Geographic Scope 34

2.3. Years Considered For The Study 35

2.4. Currency And Pricing 35

2.5. Research Methodology 36

2.6. Primary Interviews With Key Opinion Leaders 40

2.7. Secondary Sources 41

2.8. Assumptions 41

3. Market Overview 42

3.1. Drivers 44

3.1.1. Significant Decline In Fertility Rates 44

3.1.2. Rising Public Awareness Among The Female Population 45

3.1.3. Increasing Number Of Gynaecological Disorders 45

3.1.4. Technological Advancements And Innovative Testing Products 45

3.2. Restraints 46

3.2.1. High Cost Of Ovulation Testing 46

3.2.2. Accuracy Issues With Testing Kits 46

3.3. Opportunities 47

3.3.1. Reduction In The Cost Of Infertility Treatment 47

3.3.2. Emergence Of Combination Testing Kits 47

3.4. Challenges 47

3.4.1. Stringent Regulatory Scenario 47

3.4.2. Infertility Considered As Social Taboo 47

4. Executive Summary 48

5. Premium Insights 50

6. Europe Infertility Testing Market, By Type 53

6.1. Overview 54

6.2. Female Infertility Testing 56

6.2.1. Ovulation Testing 57

6.2.2. Hysterosalpingography 57

6.2.3. Laparoscopy 57

6.2.4. Transvaginal Ultrasound 58

6.2.5. Ovarian Reserve Testing 58

6.2.6. Hormone Testing 58

6.2.7. Others 58

6.3. Male Infertility Testing 59

6.3.1. Dna Fragmentation 60

6.3.2. Oxidative Stress Analysis 60

6.3.3. Sperm Penetration Assay 60

6.3.4. Computer Aided Semen Analysis 61

6.3.5. Sperm Agglutination Assay 61

6.3.6. Microscopic Examination 61

6.3.7. Others 61

7. Europe Infertility Testing Market, By Test Kits 62

7.1. Overview 63

7.2. Follicular Stimulating Hormone (Fsh) Urine Test Kits 65

7.3. Luteinizing Hormone (Lh) Urine Test Kits 66

7.4. Human Chorionic Gonadotropin (Hcg) Hormone

Blood Test Kits 67

7.5. Other Test Kits 68

8. Europe Infertility Testing Market, By Prescription Mode 69

8.1. Overview 70

8.2. Prescription Based 72

8.3. Over The Counter (Otc) Based 73

9. Europe Infertility Testing Market, By Distribution Channel 74

9.1. Overview 75

9.2. Hospitals Pharmacies 77

9.3. Online Pharmacies 78

9.4. Pharmacies & Drug Stores 79

10. Europe Infertility Testing Market, By End Users 80

10.1. Overview 81

10.2. Fertility Centers 83

10.3. Hospitals And Clinics 84

10.4. Research Institutes 85

10.5. Cryobanks 86

11. Europe Infertility Testing Market, By Geography 87

11.1. Europe 118

11.1.1. Germany 129

11.1.2. France 134

11.1.3. U.K. 138

11.1.4. Italy 142

11.1.5. Spain 147

11.1.6. Russia 152

11.1.7. Turkey 156

11.1.8. Belgium 160

11.1.9. Netherlands 164

11.1.10. Switzerland 169

11.1.11. Rest Of Europe 173

12. Europe Infertility Testing Market, Company Landscape 266

12.1. Company Share Analysis: Europe 268

13. Company Profiles 270

13.1. Babystart Ltd 270

13.1.1. Company Overview 270

13.1.2. Babystart Ltd: Company Snapshot 270

13.1.3. Product Portfolio 271

13.1.4. Recent Developments 271

13.2. Biozhena Corporation 272

13.2.1. Company Overview 272

13.2.2. Biozhena Corporation:Company Snapshot 272

13.2.3. Product Portfolio 272

13.2.4. Recent Developments 272

13.3. Quidel Corporation 273

13.3.1. Company Overview 273

13.3.2. Quidel Corporation: Revenue Analysis 273

13.3.3. Product Portfolio 274

13.3.4. Recent Developments 274

13.4. Alere Inc. 275

13.4.1. Company Overview 275

13.4.2. Alere Inc.: Revenue Analysis 275

13.4.3. Product Portfolio 276

13.4.4. Recent Developments 276

13.5. Biomerieux 277

13.5.1. Company Overview 277

13.5.2. Biomerieux: Revenue Analysis 277

13.5.3. Product Portfolio 278

13.5.4. Recent Developments 278

13.6. Spd Swiss Precision Diagnostics Gmbh 279

13.6.1. Company Overview 279

13.6.2. Spd Swiss Precision Diagnostics Gmbh: Company Snapshot 279

13.6.3. Product Portfolio 280

13.6.4. Recent Developments 280

13.7. Procter & Gamble 281

13.7.1. Company Overview 281

13.7.2. Procter & Gamble: Revenue Analysis 281

13.7.3. Product Portfolio 282

13.7.4. Recent Developments 282

13.8. Scsa Diagnostics, Inc. 283

13.8.1. Company Overview 283

13.8.2. Scsa Diagnostics, Inc: Company Snapshot 283

13.8.3. Product Portfolio 283

13.8.4. Recent Developments 283

13.9. Andrology Solutions 284

13.9.1. Company Overview 284

13.9.2. Andrology Solutions: Company Snapshot 284

13.9.3. Product Portfolio 285

13.9.4. Recent Developments 285

13.10. Atlas Medical Uk 286

13.10.1. Company Overview 286

13.10.2. Atlas Medical Uk: Company Snapshot 286

13.10.3. Product Portfolio 286

13.10.4. Recent Developments 286

13.11. Halotech Dna 287

13.11.1. Company Overview 287

13.11.2. Halotech Dna: Company Snapshot 287

13.11.3. Product Portfolio 288

13.11.4. Recent Developments 288

13.12. Sa Scientific 289

13.12.1. Company Overview 289

13.12.2. Sa Scientific: Company Snapshot 289

13.12.3. Product Portfolio 289

13.12.4. Recent Developments 289

13.13. Gem Medic Technology Co.,Ltd 290

13.13.1. Company Overview 290

13.13.2. Gem Medic Technology Co., Ltd: Company Snapshot 290

13.13.3. Product Portfolio 291

13.13.4. Recent Developments 292

13.14. Merck Kgaa 293

13.14.1. Company Overview 293

13.14.2. Merck Kgaa: Revenue Analysis 293

13.14.3. Product Portfolio 294

13.14.4. Recent Developments 294

14. Related Reports 295

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Merck KGaA

Proctor & Gamble.

bioMerieux SA

VIDAS Fertility panel,

BIONEXIA hCG Combo

Company Profile

Company Profile Title

The Europe Infertility Testing Market is accounted to reach USD 5,786.90 million by 2024, from USD 3,390.16 million in 2016 growing at a CAGR of 7.0% in the forecast period 2017 to 2024.

The major factors driving the growth of market are raising public awareness among the female population and increasing number of gynecological disorders

The key market players for Europe Infertility Testing Market are listed below:

The Europe Infertility Testing Market is accounted to reach USD 5,786.90 million by 2024, from USD 3,390.16 million in 2016 growing at a CAGR of 7.0% in the forecast period 2017 to 2024.

The major factors driving the growth of market are raising public awareness among the female population and increasing number of gynecological disorders

The key market players for Europe Infertility Testing Market are listed below:

Merck KGaA

Proctor & Gamble.

bioMerieux SA

VIDAS Fertility panel,

BIONEXIA hCG Combo

The market is further segmented into:

Type

Material

End User

Geography

The Europe infertility testing market is segmented on the basis of type, test kits, prescription mode, distribution channel and end user.

Based on type, the global infertility testing market is segmented into female infertility testing and male infertility testing. The infertility testing market is dominated by female infertility testing with 57.6% market share in 2017, growing at the highest CAGR of 7.5% in the forecast period. Based on type, female infertility testing is further segmented into ovulation testing, hysterosalpingography, laparoscopy, transvaginal ultrasound, ovarian reserve testing, hormone tests and others. Male infertility testing is sub segmented into DNA fragmentation, oxidative stress analysis, sperm penetration assay, computer aided semen analysis, sperm agglutination, microscopic examination and others.

Based on of test kits are further sub divided into human Follicular Stimulating Hormone (FSH) urine test kits, luteinizing hormone (LH) urine test kits, human chorionic gonadotropin (HCG) hormone blood test kits and others. In 2017, the Luteinizing Hormone (LH) Urine Test kits are expected to dominate the market with 40.3% market share

Based on prescription mode, the global infertility testing market is segmented into prescription-based and over the counter (OTC) based. In 2017, over the counter (OTC) segment is expected to dominate the market with 82.56% market share.

Based on distribution channel, the global infertility testing market is classified into hospitals pharmacies, online pharmacies and pharmacies & drug stores. In 2017, the pharmacies & drug stores are expected to dominate the market with 49.6% market share.

Based on end user, the global infertility testing market is classified into fertility centers, hospitals and clinics, research institutes and cryobanks. In 2017, the Fertility Centres are expected to dominate the market with 39.7% market share.

Based on geography, the Europe Infertility Testing market is segmented into geographical regions, such as,

Germany,

United Kingdom,

France,

Spain,

Italy,

Russia,

Turkey,

Belgium,

Nether lands,

Switzerland,

Rest of Europe

Covered in this report

The report covers the present scenario and the growth prospects of the Europe Infertility Testing market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Merck KGaA

Proctor & Gamble.

bioMerieux SA

VIDAS Fertility panel,

BIONEXIA hCG Combo

The market is further segmented into:

Type

Material

End User

Geography

The Europe infertility testing market is segmented on the basis of type, test kits, prescription mode, distribution channel and end user.

Based on type, the global infertility testing market is segmented into female infertility testing and male infertility testing. The infertility testing market is dominated by female infertility testing with 57.6% market share in 2017, growing at the highest CAGR of 7.5% in the forecast period. Based on type, female infertility testing is further segmented into ovulation testing, hysterosalpingography, laparoscopy, transvaginal ultrasound, ovarian reserve testing, hormone tests and others. Male infertility testing is sub segmented into DNA fragmentation, oxidative stress analysis, sperm penetration assay, computer aided semen analysis, sperm agglutination, microscopic examination and others.

Based on of test kits are further sub divided into human Follicular Stimulating Hormone (FSH) urine test kits, luteinizing hormone (LH) urine test kits, human chorionic gonadotropin (HCG) hormone blood test kits and others. In 2017, the Luteinizing Hormone (LH) Urine Test kits are expected to dominate the market with 40.3% market share

Based on prescription mode, the global infertility testing market is segmented into prescription-based and over the counter (OTC) based. In 2017, over the counter (OTC) segment is expected to dominate the market with 82.56% market share.

Based on distribution channel, the global infertility testing market is classified into hospitals pharmacies, online pharmacies and pharmacies & drug stores. In 2017, the pharmacies & drug stores are expected to dominate the market with 49.6% market share.

Based on end user, the global infertility testing market is classified into fertility centers, hospitals and clinics, research institutes and cryobanks. In 2017, the Fertility Centres are expected to dominate the market with 39.7% market share.

Based on geography, the Europe Infertility Testing market is segmented into geographical regions, such as,

Germany,

United Kingdom,

France,

Spain,

Italy,

Russia,

Turkey,

Belgium,

Nether lands,

Switzerland,

Rest of Europe

Covered in this report

The report covers the present scenario and the growth prospects of the Europe Infertility Testing market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Scope

Table Of Contents

1. Introduction 29

1.1. Objectives Of The Study 29

1.2. Market Definition 29

1.3. Overview Of Europe Infertility Testing Market 29

1.4. Currency And Pricing 30

1.5. Limitation 30

1.6. Markets Covered 31

2. Market Segmentation 33

2.1. Markets Covered 33

2.2. Geographic Scope 34

2.3. Years Considered For The Study 35

2.4. Currency And Pricing 35

2.5. Research Methodology 36

2.6. Primary Interviews With Key Opinion Leaders 40

2.7. Secondary Sources 41

2.8. Assumptions 41

3. Market Overview 42

3.1. Drivers 44

3.1.1. Significant Decline In Fertility Rates 44

3.1.2. Rising Public Awareness Among The Female Population 45

3.1.3. Increasing Number Of Gynaecological Disorders 45

3.1.4. Technological Advancements And Innovative Testing Products 45

3.2. Restraints 46

3.2.1. High Cost Of Ovulation Testing 46

3.2.2. Accuracy Issues With Testing Kits 46

3.3. Opportunities 47

3.3.1. Reduction In The Cost Of Infertility Treatment 47

3.3.2. Emergence Of Combination Testing Kits 47

3.4. Challenges 47

3.4.1. Stringent Regulatory Scenario 47

3.4.2. Infertility Considered As Social Taboo 47

4. Executive Summary 48

5. Premium Insights 50

6. Europe Infertility Testing Market, By Type 53

6.1. Overview 54

6.2. Female Infertility Testing 56

6.2.1. Ovulation Testing 57

6.2.2. Hysterosalpingography 57

6.2.3. Laparoscopy 57

6.2.4. Transvaginal Ultrasound 58

6.2.5. Ovarian Reserve Testing 58

6.2.6. Hormone Testing 58

6.2.7. Others 58

6.3. Male Infertility Testing 59

6.3.1. Dna Fragmentation 60

6.3.2. Oxidative Stress Analysis 60

6.3.3. Sperm Penetration Assay 60

6.3.4. Computer Aided Semen Analysis 61

6.3.5. Sperm Agglutination Assay 61

6.3.6. Microscopic Examination 61

6.3.7. Others 61

7. Europe Infertility Testing Market, By Test Kits 62

7.1. Overview 63

7.2. Follicular Stimulating Hormone (Fsh) Urine Test Kits 65

7.3. Luteinizing Hormone (Lh) Urine Test Kits 66

7.4. Human Chorionic Gonadotropin (Hcg) Hormone

Blood Test Kits 67

7.5. Other Test Kits 68

8. Europe Infertility Testing Market, By Prescription Mode 69

8.1. Overview 70

8.2. Prescription Based 72

8.3. Over The Counter (Otc) Based 73

9. Europe Infertility Testing Market, By Distribution Channel 74

9.1. Overview 75

9.2. Hospitals Pharmacies 77

9.3. Online Pharmacies 78

9.4. Pharmacies & Drug Stores 79

10. Europe Infertility Testing Market, By End Users 80

10.1. Overview 81

10.2. Fertility Centers 83

10.3. Hospitals And Clinics 84

10.4. Research Institutes 85

10.5. Cryobanks 86

11. Europe Infertility Testing Market, By Geography 87

11.1. Europe 118

11.1.1. Germany 129

11.1.2. France 134

11.1.3. U.K. 138

11.1.4. Italy 142

11.1.5. Spain 147

11.1.6. Russia 152

11.1.7. Turkey 156

11.1.8. Belgium 160

11.1.9. Netherlands 164

11.1.10. Switzerland 169

11.1.11. Rest Of Europe 173

12. Europe Infertility Testing Market, Company Landscape 266

12.1. Company Share Analysis: Europe 268

13. Company Profiles 270

13.1. Babystart Ltd 270

13.1.1. Company Overview 270

13.1.2. Babystart Ltd: Company Snapshot 270

13.1.3. Product Portfolio 271

13.1.4. Recent Developments 271

13.2. Biozhena Corporation 272

13.2.1. Company Overview 272

13.2.2. Biozhena Corporation:Company Snapshot 272

13.2.3. Product Portfolio 272

13.2.4. Recent Developments 272

13.3. Quidel Corporation 273

13.3.1. Company Overview 273

13.3.2. Quidel Corporation: Revenue Analysis 273

13.3.3. Product Portfolio 274

13.3.4. Recent Developments 274

13.4. Alere Inc. 275

13.4.1. Company Overview 275

13.4.2. Alere Inc.: Revenue Analysis 275

13.4.3. Product Portfolio 276

13.4.4. Recent Developments 276

13.5. Biomerieux 277

13.5.1. Company Overview 277

13.5.2. Biomerieux: Revenue Analysis 277

13.5.3. Product Portfolio 278

13.5.4. Recent Developments 278

13.6. Spd Swiss Precision Diagnostics Gmbh 279

13.6.1. Company Overview 279

13.6.2. Spd Swiss Precision Diagnostics Gmbh: Company Snapshot 279

13.6.3. Product Portfolio 280

13.6.4. Recent Developments 280

13.7. Procter & Gamble 281

13.7.1. Company Overview 281

13.7.2. Procter & Gamble: Revenue Analysis 281

13.7.3. Product Portfolio 282

13.7.4. Recent Developments 282

13.8. Scsa Diagnostics, Inc. 283

13.8.1. Company Overview 283

13.8.2. Scsa Diagnostics, Inc: Company Snapshot 283

13.8.3. Product Portfolio 283

13.8.4. Recent Developments 283

13.9. Andrology Solutions 284

13.9.1. Company Overview 284

13.9.2. Andrology Solutions: Company Snapshot 284

13.9.3. Product Portfolio 285

13.9.4. Recent Developments 285

13.10. Atlas Medical Uk 286

13.10.1. Company Overview 286

13.10.2. Atlas Medical Uk: Company Snapshot 286

13.10.3. Product Portfolio 286

13.10.4. Recent Developments 286

13.11. Halotech Dna 287

13.11.1. Company Overview 287

13.11.2. Halotech Dna: Company Snapshot 287

13.11.3. Product Portfolio 288

13.11.4. Recent Developments 288

13.12. Sa Scientific 289

13.12.1. Company Overview 289

13.12.2. Sa Scientific: Company Snapshot 289

13.12.3. Product Portfolio 289

13.12.4. Recent Developments 289

13.13. Gem Medic Technology Co.,Ltd 290

13.13.1. Company Overview 290

13.13.2. Gem Medic Technology Co., Ltd: Company Snapshot 290

13.13.3. Product Portfolio 291

13.13.4. Recent Developments 292

13.14. Merck Kgaa 293

13.14.1. Company Overview 293

13.14.2. Merck Kgaa: Revenue Analysis 293

13.14.3. Product Portfolio 294

13.14.4. Recent Developments 294

14. Related Reports 295

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Merck KGaA

Proctor & Gamble.

bioMerieux SA

VIDAS Fertility panel,

BIONEXIA hCG Combo